Laura Spring

TL;DR: It is shown that two classes of cytotoxic drugs broadly employed in pre-operative (neoadjuvant) breast cancer therapy, taxanes and anthracyclines, elicit tumour-derived EVs with enhanced pro-metastatic capacity.

TL;DR: The similar outcomes with or without adjuvant chemotherapy in patients who attain pCR likely reflects tumor biology and systemic clearance of micrometastatic disease, highlighting the potential of escalation/deescalation strategies in the adjUvant setting based on neoadjuvant response.

TL;DR: Neoadjuvant endocrine therapy, even as monotherapy, is associated with similar response rates as neoadjuant combination chemotherapy but with significantly lower toxicity, suggesting that NET needs to be reconsidered as a potential option in the appropriate setting.

TL;DR: This is the first clinical report to describe the emergence of somatic RB1 mutations after exposure to palbociclib or ribocic lib, in patients with metastatic breast cancer.

TL;DR: A number of clinical trials are exploring several important questions regarding treatment sequencing, combinatorial strategies, and the use of CDK4/6 inhibitors in the adjuvant and neoadjuvant settings, thereby further expanding and refining the clinical application of CDk4/ 6 inhibitors for patients with breast cancer.